ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för pexidartinib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

13 träffar

Bibliografisk träff 2019-12-11

PLX3397 inhibits the accumulation of intra-tumoral macrophages and improves bromodomain and extra-terminal inhibitor efficacy in melanoma.

Erkes DA, Rosenbaum SR, Field CO, Chervoneva I, Villanueva J, Aplin AE.

Pigment Cell Melanoma Res · research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1111/pcmr.12845

Bibliografisk träff 2019-11-01

Pexidartinib: First Approval.

Lamb YN.

Drugs · review-article; review; journal article · DOI 10.1007/s40265-019-01210-0

Bibliografisk träff 2019-06-21

Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors.

Wesolowski R, Sharma N, Reebel L, Rodal MB, Peck A, West BL, Marimuthu A, Severson P, Karlin DA, Dowlati A, Le MH, Coussens LM, Rugo HS.

Ther Adv Med Oncol · research-article; journal article · DOI 10.1177/1758835919854238

Bibliografisk träff 2019-06-19

Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.

Tap WD, Gelderblom H, Palmerini E, Desai J, Bauer S, Blay JY, Alcindor T, Ganjoo K, Martín-Broto J, Ryan CW, Thomas DM, Peterfy C, Healey JH, van de Sande M, Gelhorn HL, Shuster DE, Wang Q, Yver A, Hsu HH, Lin PS, Tong-Starksen S, Stacchiotti S, Wagner AJ, ENLIVEN investigators.

Lancet · clinical trial, phase iii; research-article; randomized controlled trial; journal article · DOI 10.1016/s0140-6736(19)30764-0

Bibliografisk träff 2019-06-18

A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor.

Rosenbaum E, Kelly C, D'Angelo SP, Dickson MA, Gounder M, Keohan ML, Movva S, Condy M, Adamson T, Mcfadyen CR, Antonescu CR, Hwang S, Singer S, Qin LX, Tap WD, Chi P.

Oncologist · other; research support, non-u.s. gov't; clinical trial, phase i; journal article; research support, n.i.h., extramural · DOI 10.1634/theoncologist.2019-0418

Bibliografisk träff 2019-06-14

A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel.

Piawah S, Hyland C, Umetsu SE, Esserman LJ, Rugo HS, Chien AJ.

NPJ Breast Cancer · journal article; case reports; case-report · DOI 10.1038/s41523-019-0112-z

Bibliografisk träff 2019-04-01

[Pexidartinib inhibits the aggregation of monocytes into tumor microenvironment and reduces the number of M2 tumor-associated macrophages].

Li X, Jue L, Wang S, Pang X.

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi · journal article

Bibliografisk träff 2019-03-29

The CSF1 receptor inhibitor pexidartinib (PLX3397) reduces tissue macrophage levels without affecting glucose homeostasis in mice.

Merry TL, Brooks AES, Masson SW, Adams SE, Jaiswal JK, Jamieson SMF, Shepherd PR.

Int J Obes (Lond) · research support, non-u.s. gov't; journal article · DOI 10.1038/s41366-019-0355-7

Bibliografisk träff 2019-03-02

A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors.

Lee JH, Chen TW, Hsu CH, Yen YH, Yang JC, Cheng AL, Sasaki SI, Chiu LL, Sugihara M, Ishizuka T, Oguma T, Tajima N, Lin CC.

Invest New Drugs · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1007/s10637-019-00745-z

Bibliografisk träff 2019-01-10

Effect of the CSF1R inhibitor PLX3397 on remyelination of corpus callosum in a cuprizone-induced demyelination mouse model.

Tahmasebi F, Pasbakhsh P, Mortezaee K, Madadi S, Barati S, Kashani IR.

J Cell Biochem · research support, non-u.s. gov't; journal article · DOI 10.1002/jcb.28344

Bibliografisk träff 2018-07-10

Tenosynovial giant cell tumor: case report of a patient effectively treated with pexidartinib (PLX3397) and review of the literature.

Giustini N, Bernthal NM, Bukata SV, Singh AS.

Clin Sarcoma Res · journal article; case reports; case-report · DOI 10.1186/s13569-018-0101-2

Bibliografisk träff 2015-10-08

Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.

Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, Perry A, Huse J, Phillips J, West BL, Nolop KB, Hsu HH, Ligon KL, Molinaro AM, Prados M.

Neuro Oncol · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; journal article · DOI 10.1093/neuonc/nov245

Bibliografisk träff 2015-07-01

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.

Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH, Chmielowski B, Staddon AP, Cohn AL, Shapiro GI, Keedy VL, Singh AS, Puzanov I, Kwak EL, Wagner AJ, Von Hoff DD, Weiss GJ, Ramanathan RK, Zhang J, Habets G, Zhang Y, Burton EA, Visor G, Sanftner L, Severson P, Nguyen H, Kim MJ, Marimuthu A, Tsang G, Shellooe R, Gee C, West BL, Hirth P, Nolop K, van de Rijn M, Hsu HH, Peterfy C, Lin PS, Tong-Starksen S, Bollag G.

N Engl J Med · clinical trial, phase ii; research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1056/nejmoa1411366